Brokerages Set Intensity Therapeutics Inc. (NASDAQ:INTS) PT at $37.50

Intensity Therapeutics Inc. (NASDAQ:INTS) has received an average rating of “Moderate Buy” from the four research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $37.50.

Several equities research analysts recently commented on INTS shares. Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Weiss Ratings cut Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, April 24th. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Finally, Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th.

Intensity Therapeutics Price Performance

NASDAQ:INTS opened at $4.10 on Monday. Intensity Therapeutics has a one year low of $3.51 and a one year high of $43.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.86 and a current ratio of 4.86. The stock has a market cap of $11.06 million, a PE ratio of -0.72 and a beta of 2.77. The stock has a 50 day moving average price of $4.53 and a 200 day moving average price of $7.07.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($1.08) by $0.12. Equities research analysts expect that Intensity Therapeutics will post -2.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Intensity Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp increased its stake in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the last quarter. Geode Capital Management LLC increased its stake in Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after acquiring an additional 201,357 shares during the last quarter. Corient Private Wealth LLC acquired a new stake in Intensity Therapeutics during the fourth quarter worth $41,000. Jane Street Group LLC acquired a new stake in Intensity Therapeutics during the fourth quarter worth $26,000. Finally, Mesirow Financial Investment Management Inc. increased its stake in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after acquiring an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.